Catheter Precision (VTAK) investor relations material

Company overview and business model

• Designs, manufactures, and sells innovative medical technologies for cardiac electrophysiology, including the VIVO 3D cardiac mapping system and the LockeT suture retention device.

• Expanded into private aviation through the acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC, now operating two segments: cardiac electrophysiology and private aviation.

• VIVO System is FDA-cleared and CE Marked, with over 1,000 procedures performed in the US and EU; LockeT is FDA-registered and CE Marked, with distribution agreements in multiple regions.

• Private aviation segment generates revenue from short-haul charters and brokerage services, with plans to expand into air-taxi services in North America and the Caribbean.

Financial performance and metrics

• For the three months ended March 31, 2026, private aviation segment generated approximately $0.2 million in revenue.

• As of March 31, 2026, reported cash and cash equivalents of $0.4 million and a working capital deficit of $18.5 million, with substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Gross proceeds from private placement financings in Q1 2026 totaled $4,030,759, primarily allocated to debt repayment, corporate purposes, restructuring legacy business, and reducing operating expenses.

• No proceeds from the resale of registered shares will go to the company; all proceeds go to selling stockholders.